Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon (VSV-IFNβ-NIS), in Combination With Pembrolizumab, With Expansion Cohorts in Patients With Refractory Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; VSV-IFNbeta-NIS (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vyriad
- 06 May 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Apr 2019.
- 03 Sep 2018 New trial record